Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation

Cancer Gene Therapy volume 16, pages 246–255 (2009)Cite this article

Abstract

Recent studies have demonstrated the efficacy of targeted therapy combined with radiotherapy in head and neck squamous cell carcinoma (HNSCC). We hypothesized that a combination treatment including a replicating adenovirus armed with tissue inhibitor of metalloproteinase-2 (TIMP-2), radiation and Cisplatin will augment treatment response and reduce tumor growth in vivo of HNSCC xenografts. Both single-agent (TIMP-2 virus, radiation and Cisplatin) and the combination therapies were evaluated in vitro and in vivo. The efficacy of both single-agent and combination therapies in vivo was determined by monitoring tumor growth and immunohistochemistry. Treatment with replicative Ad-TIMP-2 virus and radiation decreased cell viability in vitro and resulted in an additional antiangiogenic response in vivo. Tumor response rates to treatment with replicative Ad-TIMP-2, radiation, Cisplatin or combination therapies ranged from limited inhibition of tumor growth of the single-agent therapy to a statistically significant additive antitumor response with the combination therapies. Replicative Ad-TIMP-2+radiation+Cisplatin in the SCC1 nude mice demonstrated the greatest response rates in tumor growth and angiogenesis. Combination of Ad-TIMP-2 gene therapy with radiation and the triple treatment group resulted in an augmented therapeutic response. This is the first report of the potential benefits of combining radiation and MMP inhibitor treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 4
Figure 5
Figure 6
Figure 7
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Lemaire F, Millon R, Young J, Cromer A, Wasylyk C, Schultz I et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2003; 89: 1940–1949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rhee JG, Li D, O’Malley Jr BW, Suntharalingam M . Combination radiation and adenovirus-mediated P16(INK4A) gene therapy in a murine model for head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2003; 65: 144–154.

    Article  CAS  PubMed  Google Scholar 

  3. Rodrigo JP, Suarez C, Ferlito A, Devaney KO, Petruzzelli GJ, Rinaldo A . Potential molecular prognostic markers for lymph node metastasis in head and neck squamous cell carcinoma. Acta Otolaryngol 2003; 123: 100–105.

    Article  PubMed  Google Scholar 

  4. Morley S, MacDonald G, Kirn D, Kaye S, Brown R, Soutar D . The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 2004; 10: 4357–4362.

    Article  CAS  PubMed  Google Scholar 

  5. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359–6366.

    CAS  PubMed  Google Scholar 

  6. Matrisian LM . The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–463.

    Article  CAS  PubMed  Google Scholar 

  7. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G . Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407–413.

    Article  CAS  PubMed  Google Scholar 

  8. McCawley LJ, Matrisian LM . Matrix metalloproteinases: they’re not just for matrix anymore!. Curr Opin Cell Biol 2001; 13: 534–540.

    Article  CAS  PubMed  Google Scholar 

  9. Huppertz B, Kertschanska S, Demir AY, Frank HG, Kaufmann P . Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their inhibitors (TIMP) during trophoblast invasion in the human placenta. Cell Tissue Res 1998; 291: 133–148.

    Article  CAS  PubMed  Google Scholar 

  10. Patterson ML, Atkinson SJ, Knauper V, Murphy G . Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 2001; 503: 158–162.

    Article  CAS  PubMed  Google Scholar 

  11. Coussens LM, Fingleton B, Matrisian LM . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–2392.

    Article  CAS  PubMed  Google Scholar 

  12. Ramnath N, Creaven PJ . Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004; 6: 96–102.

    Article  PubMed  Google Scholar 

  13. Sternlicht MD, Werb Z . How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463–516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gorogh T, Beier UH, Baumken J, Meyer JE, Hoffmann M, Gottschlich S et al. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck 2006; 28: 31–39.

    Article  PubMed  Google Scholar 

  15. Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA . Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891–2895.

    CAS  PubMed  Google Scholar 

  16. Moses MA . The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15: 180–189.

    Article  CAS  PubMed  Google Scholar 

  17. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114: 171–180.

    Article  CAS  PubMed  Google Scholar 

  18. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–578.

    Article  CAS  PubMed  Google Scholar 

  19. Indraccolo S, Minuzzo S, Gola E, Habeler W, Carrozzino F, Noonan D et al. Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. Int J Biol Markers 1999; 14: 251–256.

    Article  CAS  PubMed  Google Scholar 

  20. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001; 12: 515–526.

    Article  CAS  PubMed  Google Scholar 

  21. Gately S, Kerbel R . Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001; 7: 427–436.

    CAS  PubMed  Google Scholar 

  22. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798–806.

    CAS  PubMed  Google Scholar 

  23. Baker AH, Wilkinson GW, Hembry RM, Murphy G, Newby AC . Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. Matrix Biol 1996; 15: 383–395.

    Article  CAS  PubMed  Google Scholar 

  24. Lee CT, Park KH, Yanagisawa K, Adachi Y, Ohm JE, Nadaf S et al. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 2004; 64: 6660–6665.

    Article  CAS  PubMed  Google Scholar 

  25. Rosenthal EL, Zhang W, Talbert M, Raisch KP, Peters GE . Extracellular matrix metalloprotease inducer-expressing head and neck squamous cell carcinoma cells promote fibroblast-mediated type I collagen degradation in vitro. Mol Cancer Res 2005; 3: 195–202.

    CAS  PubMed  Google Scholar 

  26. Aznavoorian S, Moore BA, Alexander-Lister LD, Hallit SL, Windsor LJ, Engler JA . Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells. Cancer Res 2001; 61: 6264–6275.

    CAS  PubMed  Google Scholar 

  27. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453–5460.

    CAS  PubMed  Google Scholar 

  28. Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther 2005; 11: 553–562.

    Article  CAS  PubMed  Google Scholar 

  29. Murphy AN, Unsworth EJ, Stetler-Stevenson WG . Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351–358.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank C Hardy and J Sellers for expert technical assistance and S Lagan for preparation of the paper. This study was supported by the NIH Training Grant T32 CA075930.

Author information

Authors and Affiliations

  1. Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

    L R McNally & D J Buchsbaum

  2. Division of Otolaryngology and Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA

    E L Rosenthal & W Zhang

Authors
  1. L R McNally
    View author publications

    Search author on:PubMed Google Scholar

  2. E L Rosenthal
    View author publications

    Search author on:PubMed Google Scholar

  3. W Zhang
    View author publications

    Search author on:PubMed Google Scholar

  4. D J Buchsbaum
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to D J Buchsbaum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McNally, L., Rosenthal, E., Zhang, W. et al. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation. Cancer Gene Ther 16, 246–255 (2009). https://doi.org/10.1038/cgt.2008.76

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/cgt.2008.76

Keywords

Search

Advanced search

Quick links